Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

HC Wainwright & Co. Initiates Coverage On Hoth Therapeutics with Buy Rating, Announces Price Target of $4

Author: Benzinga Newsdesk | February 05, 2024 07:33am
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Hoth Therapeutics (NASDAQ:HOTH) with a Buy rating and announces Price Target of $4.

Posted In: HOTH


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist